Answers are grounded in this paper and cite their sources.
Background: Chronic obstructive pulmonary disease (COPD) is characterized by high rates of morbidity, disability, and mortality. Traditional treatments often fail to adequately control the symptoms of advanced disease, particularly refractory dyspnea, and additional therapeutic options are needed. Opioids have been proposed as a potential option for symptom control in patients with COPD. Methods: To evaluate the efficacy of opioid therapy in COPD, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, Medline, Web of Science, and PubMed for randomized controlled trials (RCTs) published from inception to May 2022. Two authors independently extracted data from eligible trials and assessed the risk of bias using the tool developed by the Cochrane Collaboration. Standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs) were used for continuous outcomes, and odds ratios (ORs) with 95% CIs were used for dichotomous outcomes. Results: A total of 439 references were screened, of which 10 RCTs met the inclusion criteria. Compared with control, opioids significantly reduced dyspnea, with an effect that exceeded the minimal clinically important difference (MCID) threshold (SMD = − 0.4, 95% CI −0.6 to −0.2, P ≤ .001, I 2 = 45.8%). Opioids had no significant effect on forced expiratory volume in one second (FEV 1 ; SMD = 0.1, 95% CI −0.3 to 0.4, P = .715, I 2 = 0%) or on exercise capacity (SMD = 0.2, 95% CI −0.1 to 0.6, P = .217, I 2 = 0%). Conclusion: For patients with COPD, opioid therapy was associated with a clinically meaningful reduction in refractory dyspnea but did not improve lung function or exercise capacity. Because the available evidence is derived from a small number of older trials with modest sample sizes and clinical heterogeneity, these findings should be interpreted with caution. Opioids are not recommended as first-line therapy; low-dose opioids may be considered as an adjunct for refractory dyspnea in selected patients with advanced COPD after optimal standard treatment has been provided.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: